PRUEBA INMUNOENZIMÁTICA INDIRECTA PARA DETERMINAR ANTICUERPOS IGG+IGM FRENTE A LEISHMANIA INFANTUM.
Mexico·Clase I·III. Agentes de
diagnóstico·KABLA COMERCIAL, S.A.
DE C.V.·Registered July 12, 2024- Risk Class / Clase de Riesgo
- Clase I
- Product Type (Spanish)
- III. Agentes de diagnóstico
- Product Type (English)
- III. Agentes de diagnóstico
- Trade Name (Spanish)
- VIRCELL LEISHMANIA ELISA IGG+IGM.
- Trade Name (English)
- VIRCELL LEISHMANIA ELISA IGG+IGM.
- Analysis ID
- 1969R2024 SSA
- Registration Date
- July 12, 2024
- Name (Spanish)
- KABLA COMERCIAL, S.A. DE C.V.
- Name (English)
- KABLA COMERCIAL, S.A. DE C.V.
Access comprehensive regulatory information for PRUEBA INMUNOENZIMÁTICA INDIRECTA PARA DETERMINAR ANTICUERPOS IGG+IGM FRENTE A LEISHMANIA INFANTUM. (PRUEBA INMUNOENZIMÁTICA INDIRECTA PARA DETERMINAR ANTICUERPOS IGG+IGM FRENTE A LEISHMANIA INFANTUM.) in the Mexico medical device market through Pure Global AI's free database. This Clase I medical device is registered under COFEPRIS analysis ID 1969R2024 SSA and manufactured by KABLA COMERCIAL, S.A. DE C.V.. The device was registered on July 12, 2024.
This page provides complete registration details including product type (III. Agentes de diagnóstico), manufacturer information, and regulatory compliance data from the official Mexico COFEPRIS medical device database. Pure Global AI offers free access to Mexico's complete medical device registry with bilingual Spanish/English support, helping global MedTech companies navigate COFEPRIS regulations efficiently.